80 related articles for article (PubMed ID: 12238330)
1. Effect of a hypoxic cell sensitizer doranidazole on the radiation-induced apoptosis of mouse L5178Y lymphoma cells.
Aoki M; Furusawa Y; Shibamoto Y; Kobayashi A; Tsujitani M
J Radiat Res; 2002 Jun; 43(2):161-6. PubMed ID: 12238330
[TBL] [Abstract][Full Text] [Related]
2. Radiosensitivity of human pancreatic cancer cells in vitro and in vivo, and the effect of a new hypoxic cell sensitizer, doranidazole.
Shibamoto Y; Kubota T; Kishii K; Tsujitani M
Radiother Oncol; 2000 Aug; 56(2):265-70. PubMed ID: 10927148
[TBL] [Abstract][Full Text] [Related]
3. In vivo efficacy and pharmacokinetics of a new hypoxic cell radiosensitizer doranidazole in SUIT-2 human pancreatic cancer xenografted in mouse pancreas.
Matsuoka H; Shibamoto Y; Kubota T; Tsujitani M; Majima T
Oncol Rep; 2000; 7(1):23-6. PubMed ID: 10601585
[TBL] [Abstract][Full Text] [Related]
4. The radiosensitizing effect of doranidazole on human colorectal cancer cells exposed to high doses of irradiation.
Zhang L; Gong A; Ji J; Wu Y; Zhu X; Lv S; Lv H; Sun X
BMC Cancer; 2007 Oct; 7():188. PubMed ID: 17919337
[TBL] [Abstract][Full Text] [Related]
5. Enhanced local tumour control after single or fractionated radiation treatment using the hypoxic cell radiosensitizer doranidazole.
Murata R; Tsujitani M; Horsman MR
Radiother Oncol; 2008 Jun; 87(3):331-8. PubMed ID: 18375007
[TBL] [Abstract][Full Text] [Related]
6. Effects of hypoxic cell radiosensitizer doranidazole (PR-350) on the radioresponse of murine and human tumor cells in vitro and in vivo.
Yahiro T; Masui S; Kubota N; Yamada K; Kobayashi A; Kishii K
J Radiat Res; 2005 Sep; 46(3):363-72. PubMed ID: 16210793
[TBL] [Abstract][Full Text] [Related]
7. The prospective application of a hypoxic radiosensitizer, doranidazole to rat intracranial glioblastoma with blood brain barrier disruption.
Yasui H; Asanuma T; Kino J; Yamamori T; Meike S; Nagane M; Kubota N; Kuwabara M; Inanami O
BMC Cancer; 2013 Mar; 13():106. PubMed ID: 23496909
[TBL] [Abstract][Full Text] [Related]
8. Phase Ia study of a hypoxic cell sensitizer doranidazole (PR-350) in combination with conventional radiotherapy.
Nemoto K; Shibamoto Y; Ohmagari J; Baba Y; Ebe K; Ariga H; Takai Y; Ouchi A; Sasai K; Shinozaki M; Tsujitani M; Sakaguchi M; Yamada S; Sakamoto K
Anticancer Drugs; 2001 Jan; 12(1):1-6. PubMed ID: 11272282
[TBL] [Abstract][Full Text] [Related]
9. Radiation-chemical properties of the hypoxic cell radiosensitizer doranidazole (PR-350).
Kuwabara M; Iida Y; Inanami O; Sawamura S; Yokoyama K; Tsujitani M
J Radiat Res; 2002 Mar; 43(1):77-88. PubMed ID: 12056332
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of novel hypoxic cell sensitiser doranidazole in the treatment of locally advanced pancreatic cancer: long-term results of a placebo-controlled randomised study.
Karasawa K; Sunamura M; Okamoto A; Nemoto K; Matsuno S; Nishimura Y; Shibamoto Y
Radiother Oncol; 2008 Jun; 87(3):326-30. PubMed ID: 18342968
[TBL] [Abstract][Full Text] [Related]
11. Preclinical study on hypoxic radiosensitizing effects of glycididazole in comparison with those of doranidazole
Yasui H; Kubota N; Nishizumi J; Sakai Y; Yamamori T; Inanami O
Oncol Lett; 2018 Feb; 15(2):1993-1998. PubMed ID: 29434899
[TBL] [Abstract][Full Text] [Related]
12. PR-000350, a novel hypoxic radiosensitizer, enhances tumor cell killing by promoting apoptosis preferentially in the S-phase fraction.
Kuno Y; Shinomiya N
Apoptosis; 2000 Feb; 5(1):69-77. PubMed ID: 11227494
[TBL] [Abstract][Full Text] [Related]
13. Hypoxia and etanidazole alter radiation-induced apoptosis in HL60 cells but not in MOLT-4 cells.
Inanami O; Sugihara K; Okui T; Hayashi M; Tsujitani M; Kuwabara M
Int J Radiat Biol; 2002 Apr; 78(4):267-74. PubMed ID: 12020438
[TBL] [Abstract][Full Text] [Related]
14. A nitroimidazole derivative, PR-350, enhances the killing of pancreatic cancer cells exposed to high-dose irradiation under hypoxia.
Mizumoto K; Qian LW; Zhang L; Nagai E; Kura S; Tanaka M
J Radiat Res; 2002 Mar; 43(1):43-51. PubMed ID: 12056329
[TBL] [Abstract][Full Text] [Related]
15. Novel poly (ADP-ribose) polymerase inhibitor, AZD2281, enhances radiosensitivity of both normoxic and hypoxic esophageal squamous cancer cells.
Zhan L; Qin Q; Lu J; Liu J; Zhu H; Yang X; Zhang C; Xu L; Liu Z; Cai J; Ma J; Dai S; Tao G; Cheng H; Sun X
Dis Esophagus; 2016 Apr; 29(3):215-23. PubMed ID: 25604309
[TBL] [Abstract][Full Text] [Related]
16. Lack of differential radiosensitization of hypoxic cells in a mouse tumor at low radiation doses per fraction by cisplatin.
Sun JR; Brown JM
Radiat Res; 1993 Feb; 133(2):252-6. PubMed ID: 8438067
[TBL] [Abstract][Full Text] [Related]
17. [The Radiosensitizing Effect of Resveratrol on Hopypharyngeal Carcinoma Cell Line FADU and its Effect on the Cell Cycle].
Shao Y; Quan F; Li HH; Yao XB; Zhao Q; Zhao RM
Zhongguo Zhong Xi Yi Jie He Za Zhi; 2015 Jun; 35(6):699-703. PubMed ID: 26242123
[TBL] [Abstract][Full Text] [Related]
18. In vivo study of radiosensitizing effect of hypoxic cell radiosensitizer PR-350 on a human small cell lung cancer.
Suzuki Y; Hasegawa M; Hayakawa K; Mitsuhashi N; Niibe H
Anticancer Res; 1999; 19(5B):3993-4000. PubMed ID: 10628343
[TBL] [Abstract][Full Text] [Related]
19. Effect of the hypoxic cell sensitizer isometronidazole on local control of two human squamous cell carcinomas after fractionated irradiation.
Schreiber A; Krause M; Zips D; Dörfler A; Richter K; Vettermann S; Petersen C; Beuthien-Baumann B; Thümmler D; Baumann M
Strahlenther Onkol; 2004 Jun; 180(6):375-82. PubMed ID: 15175873
[TBL] [Abstract][Full Text] [Related]
20. Post-irradiation hypoxic incubation of X-irradiated MOLT-4 cells reduces apoptotic cell death by changing the intracellular redox state and modulating SAPK/JNK pathways.
Hamasu T; Inanami O; Tsujitani M; Yokoyama K; Takahashi E; Kashiwakura I; Kuwabara M
Apoptosis; 2005 May; 10(3):557-67. PubMed ID: 15909118
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
